搜索
Harrow Inc
HROW添加自选
41.500USD
-1.180-2.76%
收盘 06/25, 16:00（美东）报价延迟15分钟
1.55B总市值
亏损市盈率 TTM
关键数据
42.750今开
43.115最高
678.08K成交量
亏损市盈率 TTM
16.65市盈率动
--股息TTM
1.82%换手率
42.680昨收
41.250最低
22.63M成交额
亏损市盈率静
53.88市净率
0.00%股息率 TTM
-3.82%ROA
54.85052周最高
0.65量比
-17.48M净利润
37.27M总股本
-0.3849每股收益TTM
0.29Beta
-35.14%ROE
25.68052周最低
4.37%振幅
61.18%毛利率
1.55B总市值
6.88回报/风险
3.49%风险率
TradingKey Harrow Inc股票评分
单位: USD 更新时间: 2026-06-24操作建议
Harrow Inc当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在药品行业排名47/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价65.57。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Harrow Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Harrow Inc亮点
亮点风险
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
业绩高增长
公司营业收入稳步增长，连续3年增长109.15%
估值低估
公司最新PE估值-110.89，处于3年历史低位
机构加仓
最新机构持股24.67M股，环比增加1.39%
私人资本持仓
明星投资者私人资本持仓，最新持仓市值1.60M
分析师目标
根据
8
位分析师
买入
评级
65.571
目标均价
+53.28%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Harrow Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Harrow Inc简介
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
公司代码HROW
公司Harrow Inc
CEOMullery (Frank)
网址https://www.harrow.com/
相关品种
热门品种
常见问题
Harrow Inc(HROW)的当前股价是多少？
Harrow Inc(HROW)的当前股价是 42.68。
Harrow Inc的股票代码是什么？
Harrow Inc的股票代码是HROW。
Harrow Inc股票的52周最高点是多少？
Harrow Inc股票的52周最高点是54.85。
Harrow Inc股票的52周最低点是多少？
Harrow Inc股票的52周最低点是25.68。
Harrow Inc的市值是多少？
Harrow Inc的市值是1.59B。
现在Harrow Inc(HROW)的股票是买入、持有还是卖出？
根据分析师评级，Harrow Inc(HROW)的总体评级为买入，目标价格为65.57。
Harrow Inc(HROW)股票的每股收益（EPS TTM）是多少
Harrow Inc(HROW)股票的每股收益（EPS TTM）是-0.14。
